ArticlePoultry science2025
Assessing the effect of beta-propiolactone inactivation on the antigenicity and immunogenicity of cluster 2.1 duck Tembusu virus.
Article in Poultry science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Inactivation of Wild Poliovirus with β-Propiolactone.Vaccines · 2026Article
- Development of whole virion inactivated Kyasanur Forest Disease vaccine candidate and its preclinical safety and efficacy evaluation.Frontiers in immunology · 2026Article
- Development of high-titer polyclonal antisera targeting a local bovine viral diarrhea virus-1a strain: A preliminary study from Indonesia.Veterinary world · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duck Tembusu virus (DTMUV), an emerging avian pathogenic flavivirus, causes severe neurological disorders and acute egg drop syndrome in ducks. Currently, several clusters of DTMUV exhibiting significant antigenic variation are circulating in Asia with distinct geographical distributions. Therefore, developing vaccines based on virus clusters specific to regions is essential. To generate an effective inactivated vaccine, the virus inactivation procedure must be optimized for each virus strain. However, no information is available on the optimal inactivation protocol for cluster 2.1 DTMUV, which predominantly circulates in several Asian countries. This study aimed to determine the effect of beta-propiolactone (BPL) inactivation on the infectivity, antigenic integrity, and immunogenicity of cluster 2.1 DTMUV. Our results demonstrated that all conditions of BPL treatment (1:2000, 1:3000, and 1:4000 (vol/vol) concentration; 24, 48, and 72 h of incubation) could completely inactivate cluster 2.1 DTMUV, as evidenced by the absence of cytopathic effect (CPE) and DTMUV antigens after 3 passages in baby hamster kidney (BHK-21) cells. However, BPL at 1:4000 (vol/vol) concentration with 24 h of incubation preserved both the total protein content and the antigenic integrity of cluster 2.1 DTMUV more effectively than other conditions. Furthermore, we found that cluster 2.1 DTMUV inactivated with BPL under this condition was safe and highly immunogenic in ducks. This was evidenced by the absence of clinical signs and the robust induction of DTMUV-specific neutralizing antibodies and T helper lymphocyte responses in immunized ducks. Overall, these findings suggest that a 1:4000 dilution of BPL with 24 h of incubation is the optimal condition for complete inactivation of cluster 2.1 DTMUV without significant loss of antigenicity and immunogenicity. This protocol can serve as a guideline for efficient cluster 2.1 DTMUV inactivation, which is valuable for vaccine and immunoassay development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.